Is Daily Baby Aspirin Considered Antiplatelet Therapy?
Yes, daily low-dose aspirin (81 mg, commonly called "baby aspirin") is definitively antiplatelet therapy and functions by irreversibly inhibiting platelet cyclooxygenase-1 enzyme and blocking thromboxane A2 production, thereby preventing platelet aggregation. 1, 2
Mechanism and Dosing
Low-dose aspirin at 75-100 mg daily (81 mg in the United States) exceeds the minimal effective dose required for complete platelet thromboxane A2 suppression. 2 This dose range provides:
- Near-complete inhibition of arachidonic acid-induced platelet aggregation 1
- Maximal antiplatelet effect while minimizing bleeding complications compared to higher doses 2, 3
- Equivalent cardiovascular protection to higher doses (162-325 mg) without the increased gastrointestinal bleeding risk 1, 3
Evidence-Based Clinical Applications
The 2025 ACC/AHA guidelines explicitly classify aspirin 75-100 mg daily as antiplatelet therapy across multiple cardiovascular conditions:
- Acute coronary syndromes: Loading dose 162-325 mg followed by maintenance 75-100 mg daily 2
- Post-stent placement: Continued indefinitely as Class I recommendation (highest evidence level) 2, 4
- Secondary prevention after MI: Reduces serious vascular events by approximately 25%, preventing 36 events per 1,000 patients over 2 years 5, 6
Relevance to Your Clinical Scenario
For a patient with a femoral pseudoaneurysm post-cardiac catheterization who is already on antiplatelet/anticoagulant therapy:
The aspirin they are taking IS antiplatelet therapy and should be considered when planning pseudoaneurysm management. 7, 8 Research demonstrates that:
- Ultrasound-guided thrombin injection successfully treats pseudoaneurysms in 87.5-92% of cases even in patients continuing aspirin therapy 7, 8
- In one study of 64 patients, 63 were on aspirin and antithrombotic therapy was not discontinued during pseudoaneurysm closure procedures 8
- The presence of antiplatelet therapy does not preclude non-surgical treatment options 9, 10
Critical Clinical Pitfall
Do not discontinue aspirin in patients with recent cardiac catheterization or coronary stents, as aspirin withdrawal increases risk of acute coronary syndrome and stent thrombosis. 4, 6 The cardiovascular risk of stopping aspirin typically outweighs the bleeding risk from the pseudoaneurysm itself. 6
For your specific patient, the 81 mg daily aspirin represents active antiplatelet therapy that must be factored into treatment decisions, but modern pseudoaneurysm management techniques (particularly ultrasound-guided thrombin injection) are highly effective despite ongoing antiplatelet therapy. 7, 8, 9